A share price of Avidity Biosciences Inc [RNA] is currently trading at $43.21, up 2.15%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The RNA shares have gain 7.86% over the last week, with a monthly amount drifted -4.55%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Avidity Biosciences Inc [NASDAQ: RNA] stock has seen the most recent analyst activity on September 17, 2025, when Roth Capital initiated its Buy rating and assigned the stock a price target of $62. On June 24, 2025, Bernstein initiated with a Outperform rating and assigned a price target of $50 on the stock. Wolfe Research started tracking the stock assigning a Outperform rating and suggested a price target of $55 on June 17, 2025. Raymond James initiated its recommendation with a Strong Buy and recommended $65 as its price target on June 11, 2025. Citigroup started tracking with a Buy rating for this stock on March 13, 2025, and assigned it a price target of $70. In a note dated March 12, 2025, BMO Capital Markets initiated an Outperform rating and provided a target price of $72 on this stock.
Avidity Biosciences Inc experienced fluctuations in its stock price throughout the past year between $21.51 and $56.00. Currently, Wall Street analysts expect the stock to reach $76 within the next 12 months. Avidity Biosciences Inc [NASDAQ: RNA] shares were valued at $43.21 at the most recent close of the market. An investor can expect a potential return of 75.89% based on the average RNA price forecast.
Analyzing the RNA fundamentals
Trailing Twelve Months sales for Avidity Biosciences Inc [NASDAQ:RNA] were 10.73M which represents 88.12% growth. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -48.63%, Pretax Profit Margin comes in at -42.48%, and Net Profit Margin reading is -42.48%. To continue investigating profitability, this company’s Return on Assets is posted at -0.33, Equity is -0.33 and Total Capital is -0.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 41.87 points at the first support level, and at 40.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 44.53, and for the 2nd resistance point, it is at 45.84.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Avidity Biosciences Inc [NASDAQ:RNA] is 9.26. In addition, the Quick Ratio stands at 9.26 and the Cash Ratio stands at 1.81. Considering the valuation of this stock, the price to sales ratio is 587.56, the price to book ratio is 4.38.
Transactions by insiders
Recent insider trading involved Hughes Steven George, Chief Medical Officer, that happened on Sep 22 ’25 when 2208.0 shares were sold. Chief Human Resources Officer, McCarthy Teresa completed a deal on Sep 15 ’25 to sell 15000.0 shares. Meanwhile, Chief Medical Officer Hughes Steven George sold 1542.0 shares on Sep 15 ’25.
